Skip to main content
Premium Trial:

Request an Annual Quote

Merrimack Gets Second Phase I SBIR Grant, for Antibody Arrays

NEW YORK, March 25 (GenomeWeb News) - Merrimack Pharmaceuticals has received a second Phase I SBIR grant from the National Cancer Institute to develop protein microarrays, the company said today.

 

The grant supports the development of antibodies for microarrays using yeast display technology. Merrimack plans to use these antibody arrays to study protein networks in signaling pathways associated with cancer and autoimmune diseases.

 

In January, Cambridge, Mass.-based Merrimack received another Phase I SBIR grant from the NCI to develop microarray technology to study apoptosis and cancer.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.